Mr Keith P Coon, OTRL | |
1000 Highway 6, Payson, UT 84651-1600 | |
(801) 465-7070 | |
(801) 465-7001 |
Full Name | Mr Keith P Coon |
---|---|
Gender | Male |
Speciality | Occupational Therapist |
Location | 1000 Highway 6, Payson, Utah |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1437373206 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
225X00000X | Occupational Therapist | 4832156-4201 (Utah) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mr Keith P Coon, OTRL 380 E 400 S, Springville, UT 84663-1958 Ph: (801) 489-5669 | Mr Keith P Coon, OTRL 1000 Highway 6, Payson, UT 84651-1600 Ph: (801) 465-7070 |
News Archive
Nanotechnology researchers have known for years that RNA, the cousin of DNA, is a promising tool for nanotherapy, in which therapeutic agents can be delivered inside the body via nanoparticles. But the difficulties of producing long-lasting, therapeutic RNA that remains stable and non-toxic while entering targeted cells have posed challenges for their progress.
ith several vaccines already in stage 3 clinical trials, a study by University of Warwick researchers and published on the preprint server medRxiv in September 2020 discusses the use of computer modeling techniques in order to achieve optimal vaccine coverage.
Treating anemia with a class of drugs known as erythropoiesis-stimulating agents (ESAs) is associated with an increased risk of venous thromboembolism (blood clots in the deep veins of the legs or in the lungs) and death among patients with cancer, according to an article in the February 27 issue of JAMA: The Journal of the American Medical Association.
A chemical found in many "BPA free" consumer products, known as bisphenol S (BPS), is just as potent as bisphenol A (BPA) in altering brain development and causing hyperactive behavior, an animal study finds.
ARYx Therapeutics, Inc. today announced that the US Food and Drug Administration has informed the Company of an additional delay in providing needed guidance on the Phase 3 development of ARYx's product candidate for the treatment of various gastrointestinal disorders, naronapride. In this latest communication with ARYx, the FDA suggests a response will not be forthcoming until July 2011 at the earliest.
› Verified 4 days ago
Michael Rex Ewell, OTR Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 55 S Professional Way, Payson, UT 84651 Phone: 801-465-9211 | |
Deana Monique Hinton, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 1551 N Main St, Payson, UT 84651 Phone: 801-465-5400 | |
Ashton Minalga, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 1551 N Main St, Payson, UT 84651 Phone: 801-465-5400 | |
Elizabeth Barnes, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 1551 N Main St, Payson, UT 84651 Phone: 801-465-5400 | |
Miranda Howell, O.T. Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 345 N 800 E, Payson, UT 84651 Phone: 801-318-0412 |